Sino Biopharmaceutical Stock

Sino Biopharmaceutical Liabilities 2024

Sino Biopharmaceutical Liabilities

33.13 B CNY

Ticker

1177.HK

ISIN

KYG8167W1380

WKN

A0CBDJ

In 2024, Sino Biopharmaceutical's total liabilities amounted to 33.13 B CNY, a -3.46% difference from the 34.32 B CNY total liabilities in the previous year.

Sino Biopharmaceutical Aktienanalyse

What does Sino Biopharmaceutical do?

Sino Biopharmaceutical Ltd is a leading biopharmaceutical company in China that focuses on research, development, production, and distribution of medications. The company is headquartered in Hong Kong and is listed on the Hong Kong Stock Exchange. The company was founded in 2000 by Dr. Tse Ping, an experienced entrepreneur in the chemical industry. The goal was to develop innovative medications that could improve people's health and lives. Since then, Sino Biopharmaceutical has become a major player in the pharmaceutical industry. Sino Biopharmaceutical's business model is based on three pillars: generics, innovative medications, and contract manufacturing. The company specializes in the development and production of generics to make affordable, high-quality medications accessible to the masses. At the same time, the company also invests in research and development of innovative medications for rare and serious diseases. Additionally, Sino Biopharmaceutical also offers contract manufacturing services to other companies. Sino Biopharmaceutical operates in four divisions: pharmaceutical manufacturing, research and development of biopharmaceutical medications, contract manufacturing, and sales and marketing activities. Pharmaceutical manufacturing includes the production of generics as well as the manufacturing of medications for specific indications. Research and development of biopharmaceutical medications focuses on the development of therapies for severe and rare diseases. Contract manufacturing involves the manufacturing process from raw material sourcing to packaging medications for other companies. Sales and marketing activities involve positioning and promoting Sino Biopharmaceutical's products in the market. Some of Sino Biopharmaceutical's well-known products include Hengrui Medicine, an anticancer medication used to treat cancer; Yigu, a medication for liver diseases; and Tongbi, a medication for osteoporosis. Sino Biopharmaceutical has a strong presence in the Chinese market, as well as the international market. The company exports its products to over 60 countries worldwide. Sino Biopharmaceutical has also become a key partner for international companies and regularly collaborates with other pharmaceutical corporations to expand their expertise in product development and manufacturing. In summary, Sino Biopharmaceutical Ltd is a major player in the pharmaceutical industry that specializes in the development and production of generics and innovative medications. There is also a focus on contract manufacturing of medications for other companies. The company has a strong presence in the Chinese market and exports its products to over 60 countries. Sino Biopharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Sino Biopharmaceutical's Liabilities

Sino Biopharmaceutical's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Sino Biopharmaceutical's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Sino Biopharmaceutical's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Sino Biopharmaceutical's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Sino Biopharmaceutical’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Sino Biopharmaceutical stock

What is the level of liabilities of Sino Biopharmaceutical this year?

Sino Biopharmaceutical has a debt balance of 33.13 B CNY this year.

What were the liabilities of Sino Biopharmaceutical compared to the previous year?

The liabilities of Sino Biopharmaceutical have increased by -3.46% dropped compared to the previous year.

What are the consequences of high debt for investors of Sino Biopharmaceutical?

High liabilities can pose a risk for investors of Sino Biopharmaceutical, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Sino Biopharmaceutical?

Low liabilities mean that Sino Biopharmaceutical has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Sino Biopharmaceutical affect the company?

An increase in liabilities of Sino Biopharmaceutical can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Sino Biopharmaceutical affect the company?

A decrease in the liabilities of Sino Biopharmaceutical can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Sino Biopharmaceutical?

Some factors that can influence the liabilities of Sino Biopharmaceutical include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Sino Biopharmaceutical so important for investors?

The liabilities of Sino Biopharmaceutical are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Sino Biopharmaceutical take to modify the liabilities?

To change its liabilities, Sino Biopharmaceutical can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Sino Biopharmaceutical pay?

Over the past 12 months, Sino Biopharmaceutical paid a dividend of 0.08 CNY . This corresponds to a dividend yield of about 2.73 %. For the coming 12 months, Sino Biopharmaceutical is expected to pay a dividend of 0.08 CNY.

What is the dividend yield of Sino Biopharmaceutical?

The current dividend yield of Sino Biopharmaceutical is 2.73 %.

When does Sino Biopharmaceutical pay dividends?

Sino Biopharmaceutical pays a quarterly dividend. This is distributed in the months of November, July, October, October.

How secure is the dividend of Sino Biopharmaceutical?

Sino Biopharmaceutical paid dividends every year for the past 26 years.

What is the dividend of Sino Biopharmaceutical?

For the upcoming 12 months, dividends amounting to 0.08 CNY are expected. This corresponds to a dividend yield of 2.84 %.

In which sector is Sino Biopharmaceutical located?

Sino Biopharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sino Biopharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sino Biopharmaceutical from 10/4/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Sino Biopharmaceutical pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Sino Biopharmaceutical in the year 2023?

In the year 2023, Sino Biopharmaceutical distributed 0.1 CNY as dividends.

In which currency does Sino Biopharmaceutical pay out the dividend?

The dividends of Sino Biopharmaceutical are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sino Biopharmaceutical

Our stock analysis for Sino Biopharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sino Biopharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.